872 Neoadjuvant chemoradiotherapy enhances T cell infiltration in pancreatic ductal adenocarcinoma but high percentage of regulatory T cells associates with poor survival

• Raul Rabadan,
• Robyn Gartrell,
• Yvonne Saenger,
• Benjamin Fullerton,
• Thomas Enzler,
• Pan Kim,
• Ladan Fazlollahi,
• Andrew Chen,
• Subha Perni,
• Stuart Weisberg,
• Emanuelle Rizk,
• Eun Jeong Oh,
• Xinzheng Guo,
• Codruta Chiuzan,
• Donna Farber,
• Helen Remotti,
• David Horowitz

Affiliations

Raul Rabadan

2Columbia University Irving Medical Center, Edgewater, NJ, USA

Robyn Gartrell

2Columbia University Irving Medical Center, Edgewater, NJ, USA

Yvonne Saenger

5Columbia University Irving Medical Center/New York Presbyterian, New York, NY, USA

Benjamin Fullerton

1Columbia University Medical Center, New York, NY, USA

Thomas Enzler

3University of Michigan Medicine, Ann Arbor, MI, USA

Pan Kim

4University of Pittsburgh Medical Center, Pittsburgh, USA

Ladan Fazlollahi

5Columbia University Irving Medical Center/New York Presbyterian, New York, NY, USA

Andrew Chen

6Vagelos College of Physicians and Surgeons, New York, NY, USA

Subha Perni

7Massachusetts General Hospital and Brigham and Women’s Hospital/Dana-Farber Cancer Institute, Boston, USA

Stuart Weisberg

5Columbia University Irving Medical Center/New York Presbyterian, New York, NY, USA

Emanuelle Rizk

2Columbia University Irving Medical Center, Edgewater, NJ, USA

Eun Jeong Oh

8Columbia University, Mailman School of Public Health, New York, USA

Xinzheng Guo

2Columbia University Irving Medical Center, Edgewater, NJ, USA

Codruta Chiuzan

2Columbia University Irving Medical Center, Edgewater, NJ, USA

Donna Farber

2Columbia University Irving Medical Center, Edgewater, NJ, USA

Helen Remotti

5Columbia University Irving Medical Center/New York Presbyterian, New York, NY, USA

David Horowitz

5Columbia University Irving Medical Center/New York Presbyterian, New York, NY, USA